Could a Once-Every-Few-Weeks shot replace daily pills for schizophrenia?

This trial compares a new long-acting injectable form of the schizophrenia drug cariprazine (called B2227) with the standard oral version, Vraylar. Researchers want to see how the body absorbs and processes each version, and whether the injectable is safe and tolerable. The study involves 84 adults with schizophrenia who receive either a single injection of B2227 or multiple doses of oral Vraylar.